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Abstract
Background: Data on the burden of mumps in South Africa are limited and the epidemiology of mumps in this
setting is not well understood. We present an analysis of mumps data in South Africa from 2012 to 2017.
Methods: This cross-sectional study included secondary data on laboratory-confirmed mumps infections from 2012
to 2017, archived at the South African National Health Laboratory Services’ data repository as well as from four
private laboratories. Mumps-specific immunoglobulin M (IgM) and/or viral nucleic acid positive results represented
acute infections. We used age-specific mid-year population estimates for each study year as denominators when
calculating annual cumulative incidence. Seasonality was based on the season that showed a peak in infections.
Results: Out of 48,580 records obtained from the public and private sectors, 46,713 (96.2%) were from the private
sector. Over the study period, there were 7494 acute infections, 7085 (94.5%) of which were recorded in the private
sector. Of these 7494 infections, 3924 (52.4%) occurred in males. The proportion of samples tested that were IgM
positive was 18.6% (1058/5682) in 2012, 15% (1016/6790) in 2013, 15.8% (1280/8093) in 2014, 15.5% (1384/8944) in
2015, 13.1% (1260/9629) in 2016 and 15.8% (1496/9442) in 2017. The cumulative incidence rate per 100,000 was
highest in children between one and 9 years throughout the study period. The cumulative incidence of infections
was highest in the Western Cape, Gauteng and the Northern Cape. Infections peaked in June and November.
Conclusion: Laboratory-confirmed mumps infections predominantly occurred in spring, affecting children below
10 years of age and individuals who were male. There were fewer tests performed in the public sector compared to
the private sector. Since only laboratory data was analysed our results represent and underestimate of disease
burden. Further studies that include clinical data are required to provide better estimates of disease burden in
South Africa.
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Background
Mumps is usually a childhood illness that mostly affects
children aged 5–9 years although adolescents and adults
can be infected [1]. In the absence of a mumps-containing
vaccine (MuCV), the annual incidence of mumps was
estimated to be between 100 and 1000 cases/100000
population [1]. By the end of 2018, 122 countries world-
wide had introduced the vaccine in their respective na-
tional immunization programmes, with the annual
reported number of cases being 499,512 worldwide [2, 3].
However, there has been reports of mumps outbreaks in
previously adequately vaccinated populations recently, in-
dicating possible waning immunity [4–10].
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Mumps is not a notifiable disease in South Africa [11].
This contributes to the sparse epidemiological data about
the disease and the baseline incidence of mumps infec-
tions not being known. Between 1999 and 2018, only two
Southern African countries (Eswatini and Zambia) fre-
quently reported mumps cases, while South Africa only
reported 24 cases in 2002 [12].
Important policy and programmatic considerations re-
garding the introduction of a MuCV into a country’s
immunization programme include the burden of mumps
disease, the efficiency of the country’s national
immunization programme, the socioeconomic impact of
the vaccine introduction, and the ability of the country to
achieve and maintain a coverage > 80% for the measles-
and rubella-containing vaccines [13]. A vaccine coverage
> 80% for the measles- and rubella-containing vaccines
demonstrates a country’s ability to achieve a similar or
higher coverage for the MuCV. A suboptimal coverage
would result in an epidemiological shift of disease, leading
to a higher incidence of mumps infections in the older
age-groups. An increase in age has been associated with
more severe disease in many childhood diseases, and in
mumps infections, this increased risk occurs more com-
monly in males compared to females [10, 14] The World
Health Organization (WHO) also recommends that
should a MuCV be introduced by a country, it should be
as two doses given at 12–18months then from 2 up to 6
years in the form of the trivalent measles-mumps-rubella
(MMR) vaccine. Mumps should also be included in the
country’s list of notifiable diseases that would be under
surveillance. By 2017, only four countries in the African
region (Seychelles, Mauritius, Cabo Verde and Algeria)
had introduced the MuCV in their respective national vac-
cination program, while in South Africa, MuCV was only
available in the private health sector as MMR and was not
part of the Extended Programme of Immunizations (EPI)
that provides vaccines to children in the public health sec-
tor [15–17].
We therefore aimed to describe the epidemiology of
laboratory-confirmed mumps infections in South Africa
between January 2012 to December 2017, with the ob-
jectives of estimating the cumulative incidence of
laboratory-confirmed infections as well as determining
whether the infections had periodic fluctuations.
Methods
Study design and setting
This was a cross-sectional study using laboratory data
from both private and public health sectors, from Janu-
ary 2012 to December 2017. The study period was
chosen because mumps data was recorded more consist-
ent in both health sectors during this period. Public sec-
tor data were obtained from the data repository of the
National Health Laboratory Service (NHLS). The NHLS
is the largest diagnostic pathology service provider in
South Africa and provides laboratory services to ≥80% of
the population through a network of over 260 laborator-
ies throughout the country [18]. Private sector data were
obtained from four private laboratories (Ampath, Lancet,
PathCare and Vermaak & Partners). Data included pa-
tient’s demographic information as well as test results.
Operational definitions
Positive mumps-specific immunoglobulin M (IgM) and/
or viral nucleic acid (NA) results represented acute in-
fections. Results positive only for mumps-specific im-
munoglobulin G (IgG) represented previous exposure to
mumps. Age-specific cumulative incidence rates were
calculated using the number of acute infections per year
as the numerator and the age-specific mid-year popula-
tion estimates as denominators [19–24]. Mid-year popu-
lation estimates for 2012 were not available, therefore
the average of estimates for 2011 and 2013 were used to
calculate the 2012 age-specific estimates. A seasonal pat-
tern was determined by the months that showed a peak
in the number of infections.
Participants, sample size and sampling
All samples tested for mumps at the NHLS and the four
private laboratories during the study period were
included.
Data management and analysis
Stata statistical software version 15 (StataCorp. 2017.
Stata Statistical Software: Release 15. College Station,
TX: StataCorp LLC) was used for data cleaning and
analysis.
Ethical considerations
Ethics approval for conducting this study was obtained
from the Faculty of Health Sciences Research Ethics
Committee of the University of Pretoria (ref. 539/2017).
Institutional clearance was also obtained from the NHLS
Academic Affairs, Research and Quality Assurance as
well as the relevant ethics committees of the respective
private laboratories.
Results
A total of 48,580 records were used in the analysis. Par-
ticipant characteristics are summarized in Table 1. Of
these records, 46,713 (96.2%) were from the private sec-
tor. There were 186 (0.4%) records with missing infor-
mation on age, 143 (0.3%) on gender, 15,993 (32.9%) on
sample type and 15,175 (31.2%) on province. There were
26,640 (54.8%) records from samples collected from fe-
males. There were 10,279 samples from children < 9
years, of which 9583 (93.2%) were from the private sec-
tor. Types of specimens submitted to both health sectors
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over the study period are shown in Fig. 1. There were
20,279 (41.7%) cerebrospinal fluid samples, and 12,144
(25.0%) blood samples (this includes samples labelled
“blood” and “blood culture”) (Fig. 1). The highest num-
ber of samples submitted overall was from Gauteng
Province 16,959 (50.8%), while the lowest number of
samples was from the Eastern Cape, Northern Cape and
Free State Provinces (343 (1%), 345 (1%) and 349 (1%)
respectively).
Overall, there were 7494 infections recorded during
the study period, 7085 (94.5%) of which were in the pri-
vate sector (Fig. 2). Most of these infections were re-
corded in 2017 (1496/7494; 20%), while the least
number of infections occurred in 2013 (1016/7494;
13.6%). Most (3061/3198; 95.7%) of the infections were
diagnosed from blood samples. Except for 2013, there
was consistently more infections amongst males
(Table 2). The highest absolute numbers of acute infec-
tions were recorded in the Gauteng (1601), Western
Cape (965) and KwaZulu Natal (626) provinces overall
(Fig. 2), however the highest cumulative incidence per
100,000 of infections occurred in Western Cape, Gau-
teng and Northern Cape, in that order (Fig. 3). On aver-
age, the cumulative incidence was highest in 2017 (1,43
cases/100000 population) and lowest in 2013 (0,60
cases/100000 population). The cumulative incidence was
high amongst children in the 1–4 and 5–9 year age
groups (Fig. 4). When the cumulative incidences of
mumps infections in these two most affected age-groups
were plotted according to geographic distribution, the
highest incidence was in the Western Cape (Figs. 5 and 6).
When the absolute numbers of infections were plotted by
month, two peaks were observed in June and November
throughout the study period (Fig. 7). The province with
the highest proportion of cases with evidence of previous
exposure to mumps exposure throughout the study period
was Gauteng (Table 3).
Discussion
In this paper, we report the number of tests positive for
mumps in South Africa between 2012 to 2017. Most of
these cases were reported by the private sector labora-
tories and occurred mostly in the 1–4 and 5–9 age
groups. This age distribution is consistent with what has
been reported in other countries during the pre-MuCV
Table 1 Characteristics of samples submitted for mumps
testing in public and private sectors, 2012–2017, (n = 48,580)
Variable Public Sector, n (%) Private Sector, n (%) Total n (%)
Gender
Female 1046 [4] 25,594 (96) 26,640 (100)
Male 788 (4) 21,009 (96) 21,797 (100)
Age
< 1 139 (9) 1423 (91) 1562 (100)
1–4 317 (7) 4080 (93) 4397 (100)
5–9 240 (6) 4080 (94) 4320 (100)
10–19 263 (4) 6061 (96) 6324 (100)
20–29 299 (4) 7184 (96) 7483 (100)
30–39 214 (2) 9866 (98) 10,080 (100)
> 40 227 (2) 14,001 (98) 14,228 (100)
Unknown 168 (90) 18 (10) 186 (100)
Province
EC 71 (21) 272 (79) 343 (100)
FS 63 (18) 286 (82) 349 (100)
GP 933 (6) 16,026 (94) 16,959 (100)
KZN 193 (2) 8116 (98) 8309 (100)
LP 51 (6) 822 (94) 873 (100)
MP 114 (8) 1245 (92) 1359 (100)
NW 67 (9) 663 (91) 730 (100)
NC 60 (17) 285 (83) 345 (100)
WC 315 (8) 3823 (92) 4138 (100)
EC Eastern Cape; FS Free State; GP Gauteng; KZN KwaZulu Natal; LP Limpopo;
MP Mpumalanga; NW North West; NC Northern Cape; WC Western Cape
Fig. 1 Types of specimens submitted for mumps testing in the public and private sectors, 2012–2017. bOther: swabs, stool, sears, saliva/sputum,
nasopharyngeal aspirates, bone marrow, amniotic fluid
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era, with most of the infections reported in children
below 10 years of age [1]. The cumulative incidence of
mumps in our setting was found to be lower than that
reported in Western countries during the pre-vaccine
era. This most likely reflects under-reporting of mumps
since the disease is neither notifiable nor under surveil-
lance. The low incidence could also mean that the re-
ported cases represent patients with more severe
presentation of the disease, such as mumps-associated
meningitis or orchitis, in whom further investigations
would have been conducted. The results could also indi-
cate diagnostic practises in our setting, with mumps pos-
sibly only being diagnosed clinically if a patient
presented with a typical presentation of parotid enlarge-
ment. This would suggest that mumps cases presenting
with other complications of the disease could have pos-
sibly been undiagnosed and therefore not be accounted
for in the analysed results. Also, had there been an out-
break of mumps during the study period, this may have
been unidentified.
There have been recent reports on resurgence of
mumps infections amongst adolescents and young
adults in overcrowded and semi-closed settings such
as communes, colleges and camps in developed coun-
tries [8–10, 14, 25]. In the United States (US), mili-
tary recruits, a sub-population that has previously
been associated with mumps outbreaks, were found
not to be involved in the resurgence of mumps infec-
tions reported between 1998 and 2007 [8]. This was
associated with the decision in 1991, to introduce the
MMR vaccine amongst recruits irrespective of previ-
ous vaccination status. Although this finding could
strengthen a case for booster doses in older age
groups, particularly those at high risk such as college stu-
dents, antibody titres have been found not to be durable,
with titres returning to pre-MMR3 dose levels 1 year after
vaccination in individuals between 18 and 24 years in a
non-outbreak setting [9]. A booster dose of the mumps
vaccination is currently recommended only in the setting
of an outbreak [9, 10, 26–28]. Although the level of pro-
tective antibodies and correlates of protection against
mumps infection are not well-defined, suggested
causes of the resurgence of infections have included
waning immunity over time due to a lack of a dur-
able T-cell mediated response, as well as antigenic
differences between vaccine and circulating mumps
strains, [1, 4, 7–10, 26–31]. As such, the mismatch
between vaccine and circulating mumps strains has
also prompted the consideration of a polyvalent vac-
cine [1, 32].
In our study, most of the samples submitted for
mumps testing were CSF and blood specimens. One
study conducted in Gauteng Province in South Africa
used CSF samples from patients who had clinical
Fig. 2 Absolute number of laboratory-confirmed acute mumps infections recorded in the public and private sectors by province, 2012–2017
Table 2 Absolute number and percentages of infections
reported in public and private sectors by gender, 2012–2017
Sex Female n (%) Male n (%) Total n (%)
2012 497 (47,02) 560 (52,98) 1057 (100)
2013 517 (51,14) 494 (48,86) 1011 (100)
2014 598 (46,79) 680 (53,21) 1278 (100)
2015 635 (46,01) 745 (53,99) 1380 (100)
2016 599 (47,65) 658 (52,35) 1257 (100)
2017 703 (47,18) 787 (52,82) 1490 (100)
Total 3549 (47,49) 3924 (52,51 7473 (100)
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presentation of central nervous system disease (meningi-
tis, encephalitis or other febrile illness with focal neuro-
logical signs) to determine the presence of mumps and
to characterise the strains, if found [16]. The study
found a low frequency of mumps-associated CNS dis-
ease [3/260 (1.2%)], and phylogenetic analysis of one de-
tected strain showed that it was a Jeryl-Lynn or RIT4385
vaccine-like strain. A suggestion made by the authors
was the establishing of a mumps surveillance
programme in the country, which would also provide
valuable mumps epidemiological data. At the time of
submitting this paper, there was no established surveil-
lance program for mumps in South Africa.
Our finding of a male predominance with regards to
infections is similar to what has been reported in other
studies [14, 33]. This has been associated with immuno-
logical differences between males and females, where fe-
males have been shown to have a stronger T-helper1 cell
(Th1) immune response, as well as having persistent and
higher antibody levels compared to males [31, 34]. Orchitis
has been reported to be the most common complication of
mumps infection, and this may also explain the higher pro-
portion of males in this study [6]. Males have also been
found to have an increased risk of complications that occur
less commonly following mumps infections such as
mumps-associated meningitis and encephalitis [6, 34].
Fig. 3 Incidence per 100,000 population of laboratory-confirmed mumps infections in the public and private sectors by province, 2012–2017
Fig. 4 Incidence per 100,000 population of laboratory-confirmed mumps infections in the public and private sectors by age-group, 2012–2017
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The seasonal pattern of mumps infections differs by
country, with this difference attributed to environmental,
host and viral factors [35]. In our study, we found that
the infections peaked in June and November. These
months represent the beginning of winter and spring re-
spectively in our setting [36]. A peak in infections in
spring and winter has been reported in Jordan [35].
Although Western Cape was seemingly the most af-
fected province with the highest average yearly inci-
dence, the second highest number of recorded samples
was from this province (second to Gauteng). Therefore,
this province may have been over-represented in the
analysis. The geographic distribution of the infections
may also be due to the differential availability of labora-
tory services in the different provinces in the country.
Formulating recommendations for introducing a
MuCV, one of the underutilized vaccines in the African
region, in South Africa’s public health sector (through
the EPI), is beyond the scope of this paper, and our
study results are also not sufficient to inform such a pol-
icy [15]. As previously mentioned, before a MuCV can
be introduced in a country, the baseline coverage of the
measles-containing vaccine (MCV) should be > 80%.
Based on the coverage data for the first and second
Fig. 5 Incidence per 100,000 of laboratory-confirmed acute infections recorded in the public and private sectors by province, 1–4 year
age-group, 2012–2017
Fig. 6 Incidence per 100,000 of laboratory-confirmed acute infections recorded in the public and private sectors by province, 5–9 year
age-group, 2012–2017
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doses of MCV (MCV1 and MCV2 respectively) in South
Africa, the MCV1 coverage ranged from 68% in 2007 to
70% in 2018 and was > 80% only during the 2014–2016
period (84% in 2014, 86% in 2015 and 85% in 2016) [37].
The MCV2 vaccine coverage estimates (also from 2007
to 2018) showed a drastic decline, with estimates ranging
from 49% in 2007 to 63% in 2016. Of note is that these
quoted proportions are WHO and UNICEF estimates,
and differ from the country’s official national and ad-
ministrative estimates, all of which were > 80% for the
MCV1 and between 70 and 95% for MCV2 between the
2007–2018 period. Further efforts in increasing the
MCV uptake may therefore be required to meet the rec-
ommended baseline MCV vaccine coverage before con-
sidering the introduction of a MuCV [12, 38, 39].
Another important consideration regarding the intro-
duction of a MuCV in South Africa’s public sector is the
vaccine’s schedule compared to that of measles. The first
dose of MuCV should be given between 12 and 18
months, and the second dose at the age of school entry
(around 6 years of age), whereas, at the time that this
paper was written, MCV was being given at 6 (first dose)
and 12months (second dose) according to the EPI
schedule [13, 17]. Subsequent to the introduction of the
MuCV, determining the effectiveness of the vaccine
would be necessary. However, this could be challenged
by the lack of knowledge regarding correlates of protec-
tion against mumps infection [26].
The main strength of our study is that we analysed
data from both the public and private health sectors.
However, our study had several limitations. Firstly, miss-
ing data could not be accounted for and information on
risk factors was not available since the secondary data
that was analysed did not include information about
clinical and medical history. Secondly, 50% of mumps
infections present non-specifically or with respiratory
symptoms, while 20–40% of infections are reportedly
asymptomatic or have mild symptoms [1, 27, 40]. These
cases may not present at health facilities and would
therefore not have been accounted for in the data that
Fig. 7 Absolute numbers of laboratory-confirmed acute infections recorded in the public and private sectors by province by month, 2012–2017
Table 3 Proportion of samples submitted for mumps testing that showed previous exposure in the public and private health
sectors, 2012–2017
Year GP n (%) KZN n (%) MP n (%) NW n (%) WC n (%) LP n (%) FS n (%) EC n (%) NC n (%) Totals n (%)
2012 618 (19) 201 (20) 30 (15) 15 (12) 2 (2) 13 (13) 0 0 0 879 (100)
2013 511 (15) 186 (18) 40 (20) 12 (10) 5 (5) 31 (32) 0 0 6 (27) 791 (100)
2014 521 (16) 196 (19) 32 (16) 16 (13) 1 (1) 15 (15) 5 (20) 6 (26) 3 (14) 795 (100)
2015 545 (16) 158 (15) 23 (11) 31 (25) 12 (12) 12 (12) 4 (16) 6 (26) 10 (45) 795 (100)
2016 519 (16) 138 (13) 39 (19) 19 (15) 41 (41) 15 (15) 11 (44) 6 (26) 3 (14) 801 (100)
2017 601 (18) 145 (14) 39 (19) 33 (26) 38 (38) 12 (12) 5 (20) 5 (22) 0 791 (100)
Total 3315 (100) 1024 (100) 203 (100) 126 (100) 99 (100) 98 (100) 25 (100) 23 (100) 22 (100) 4935 (100)
EC Eastern Cape; FS Free State; GP Gauteng; KZN KwaZulu Natal; LP Limpopo; MP Mpumalanga; NW North West; NC Northern Cape; WC Western Cape
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we reviewed. Also, data of cases of acute infection where
the diagnosis was made clinically without laboratory
confirmation would also not be included in our study.
Since mumps was not a notifiable disease in South Af-
rica at the time that this paper was written, case-based
data that could have supplemented the laboratory-based
data were also not available. The above-mentioned limi-
tations may account for the small numbers of mumps
test requests, particularly from the public health sector,
where mumps infections are likely to be diagnosed clin-
ically rather than by laboratory testing, due to consider-
ation for resources. Thirdly, we were not able to
comment on mumps-related complications in our set-
ting because information on clinical presentation or
medical history was not included in the analysed data.
Fourthly, differential availability of laboratory services
across the provinces may also have had an impact on
the completeness of the analysed data. The estimates of
acute infections presented may be an underestimation of
the true burden of mumps disease and may explain why
the cumulative incidence found in our study was lower
than the cumulative incidence of ≥100 cases/100000 that
has been reported in the pre-vaccine era in other
settings.
Conclusion
Our results showed that, in South Africa, mumps infec-
tions mostly affected children below 10 years of age,
peaked during winter and spring and predominantly af-
fected males. Fewer tests were performed in the public
compared to the private sector, which may have contrib-
uted to under-reporting of infections. Since our study
results were only based on laboratory test results, con-
ducting further studies that include analysis of clinical
data may provide further insight into disease burden in
the country.
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